Aficamten Tablets bulk supplier for pharma manufacturers

Aficamten Tablets 5 mg, 10 mg, 15 mg, 20 mg Suppliers & Bulk Manufacturers

Available Forms: Film-coated tablets

Available Strengths: 5 mg, 10 mg, 15 mg, 20 mg

Pack Sizes: Bottles or blisters of 30

Reference Brands: Myqorzo (Cytokinetics)

Aficamten (Myqorzo, Cytokinetics) is a once-daily cardiac myosin inhibitor for adults with symptomatic obstructive hypertrophic cardiomyopathy, approved by the US FDA in December 2025. PharmaTradz handles enquiries for authorised supply of the originator product (named-patient and import-permit orders), and connects developers and licensees preparing for patent and exclusivity expiry.

Ask About Access

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Aficamten Tablets? List it or send an offer →

Product Description:

In hypertrophic cardiomyopathy (HCM) the heart muscle is thickened and contracts too forcefully. In the obstructive form, the thickened wall blocks blood leaving the heart, causing breathlessness, chest pain and tiredness. Aficamten reduces the number of myosin-actin links that drive each contraction, so the muscle squeezes less hard and the obstruction eases.

The US FDA approved aficamten as Myqorzo in December 2025 for adults with symptomatic obstructive HCM, to improve exercise capacity and symptoms. It is taken once a day; the dose is adjusted step by step using echocardiograms. Its shorter half-life than mavacamten allows faster dose changes.

Sourcing notes. Aficamten is patented and there is no generic. Registration outside the US is still being built, so early demand comes through named-patient routes. Mavacamten, the first cardiac myosin inhibitor, is also listed on PharmaTradz.

How Aficamten Tablets is supplied today, and licensing ahead of patent expiry

Aficamten Tablets is a patented innovator medicine. Where its patents are in force, which today includes most major markets, it can only be supplied by the originator or its licensees, through the routes below. Patents do expire, though, and generic development and licensing deals for post-patent markets start years in advance. If you are developing Aficamten Tablets, hold a dossier for it or want to license it, talk to us.

Named-patient import Where a patient needs the product in a market where it is not registered, named-patient import is the lawful route. It requires the treating physician's documentation and authorisation from the destination regulator. We handle this pathway. Named-patient access

Authorised distribution For registered markets, supply runs through the manufacturer's authorised distribution channel. We can identify the authorised route for your market and tell you whether the product is registered there at all. Innovator sourcing

A genericised alternative Where the clinical requirement is the drug class rather than this specific molecule, there is often an off-patent alternative that is faster to register and materially cheaper. Tell us the indication and target market and we will say plainly whether one exists. Discuss alternatives

Licensing and generic development Patents expire country by country, and in many countries development and dossier filing can start before expiry under research and regulatory-review exemptions. We connect manufacturers developing this molecule, dossier holders, licensees and tech-transfer partners for markets where it is, or will become, off-patent. Partner on this molecule

Ask about Aficamten Tablets supply →

Back to Listing